IEX •
Healthcare •
Biotechnology •
Quote as of 09/08/2026 15:59
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization32.64 mln
Float54.04 mln
Earnings Date11/12/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
5.75
Transformational upside
Relative Strength
100
/ 100
Top performer
Debt / Equity
-1.22
Negative equity
ROE
-481
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
PDS Biotechnology Corporation is a Princeton, New Jersey-based clinical-stage company founded in 2005 that focuses on developing treatments designed to help the immune system fight cancer. Its lead therapy, Versamune HPV, is currently in Phase II trials targeting several HPV-related cancers, while additional candidates address conditions such as leukemia, breast, ovarian, and lung cancer. The company also has a novel flu vaccine in development and works alongside prominent partners including the National Institutes of Health and Merck.
